cabozantinib
ipsen
['congrat', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint']
important results from #cabopoint trial just released by with daily practice implications at #gu23 cabozantinib can rescue patients with mrcc that have failed in less than 6 months to standard 1st line doublet. huge congrats!!!! 
Jefe del Servicio de #Oncología Médica y Director de Investigación Clínica de la Fundación MD Anderson Cancer Center Madrid. Opinions are my own